Answers are grounded in this paper and cite their sources.
Background Predictable graft healing following anterior cruciate ligament (ACL) reconstruction remains a clinical challenge, particularly because insufficient ligamentization and tendon–bone integration may be associated with graft failure and less favorable functional outcomes. Mesenchymal stem cell (MSC)-derived secretome represents a cell-free biological approach comprising diverse bioactive molecules with potential regenerative properties, as supported by preclinical studies. This study aimed to compare pain intensity and functional outcomes at six months after ACL reconstruction using a peroneus longus tendon (PLT) autograft, with and without adjunctive intralesional administration of MSC-derived secretome. Methods This study enrolled 24 patients undergoing arthroscopic single-bundle anterior cruciate ligament (ACL) reconstruction using a peroneus longus tendon (PLT) autograft. Participants were randomly allocated in a 1:1 ratio to receive either an intralesional injection of mesenchymal stem cell (MSC)-derived secretome into the graft (secretome group, n = 12) or an equivalent-volume saline placebo (control group, n = 12). Clinical outcomes were assessed preoperatively and at 6 months postoperatively using the International Knee Documentation Committee (IKDC) Subjective Knee Evaluation Form, Tegner–Lysholm Knee Scoring Scale, and Visual Analog Scale (VAS) for pain intensity. Between-group comparisons were conducted using the independent-samples t-test or Mann–Whitney U test, and followed by ANCOVA analysis as appropriate to the distributional characteristics of the data. Statistical significance was set at p < 0.05. Results At baseline, IKDC and VAS scores did not differ significantly between the secretome and control groups (IKDC: 48.57 ± 4.91 vs. 47.51 ± 4.45, p > 0.05; VAS: 7.75 ± 0.62 in both groups, p = 1.000). At the six months follow-up, patients receiving adjunctive secretome injection demonstrated significantly higher IKDC scores than controls (86.89 ± 5.11 vs. 78.27 ± 3.91, p < 0.01). Similarly, Tegner–Lysholm scores were significantly higher in the secretome group (87.08 ± 5.16 vs. 79.33 ± 2.67, p < 0.01). Pain intensity was also significantly lower in the secretome group, as reflected by lower VAS scores (2.17 ± 0.72 vs. 3.92 ± 0.79, p < 0.001). Conclusion Adjunctive MSC-derived secretome administration during anterior cruciate ligament (ACL) reconstruction using a peroneus longus tendon (PLT) autograft was associated with higher International Knee Documentation Committee (IKDC) subjective knee scores and Tegner–Lysholm knee scores, as well as lower Visual Analog Scale (VAS) pain scores, at 6 months postoperatively compared with saline placebo. These findings suggest the potential of MSC-derived secretome as a cell-free biological adjunct to improve patient-reported knee function and reduce postoperative pain following ACL reconstruction, warranting further evaluation in larger clinical trials.
No takes yet. Share an insight, caveat, or question.
Aryana et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: